by Terry Bryant

Last year the world’s eighth largest drug maker Johnson & Johnson agreed to pay billions of dollars to resolve allegations it inappropriately promoted the antipsychotic drug Risperdal, which was one of the company’s best-selling drugs.  The investigations stretch back ten years and puts the agreement as the third-largest pharmaceutical settlement in the United States.

However, a raft of private lawsuits have emerged linking the  psychotic drug  to adverse side effects, one of the most disturbing, gynecomastia,  the abnormal development  of breast tissue in males. Risperdal produces a high level of prolactin in the body, which causes breast growth and lactation.

The multinational companies’ lack of transparency and failure to adequately provide warning labels regarding the drug’s devastating  side effects initiated a slew of personal injury  lawsuits.  Among those who have already settled was a 21-year-old victim, who alleged he suffered severe psychological trauma and had to undergo a mastectomy; surgery for the removal of breast, after taking the antipsychotic drug a child.